These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 30293948)

  • 1. [Ulipristal acetate and SPRM: A new entity for the therapeutic strategy for symptomatic myomas].
    Fernandez H
    Gynecol Obstet Fertil Senol; 2018 Nov; 46(10-11):671-672. PubMed ID: 30293948
    [No Abstract]   [Full Text] [Related]  

  • 2. Ulipristal acetate for use in moderate to severe symptoms of uterine fibroids.
    Talaulikar VS; Manyonda I
    Womens Health (Lond); 2014 Nov; 10(6):565-70. PubMed ID: 25482483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The use of selective progesterone receptor modulators in the treatment of myomas].
    Šimetka O; Klát J
    Ceska Gynekol; 2016; 81(4):317-320. PubMed ID: 27882756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in proliferating and apoptotic markers of leiomyoma following treatment with a selective progesterone receptor modulator or gonadotropin-releasing hormone agonist.
    Yun BS; Seong SJ; Cha DH; Kim JY; Kim ML; Shim JY; Park JE
    Eur J Obstet Gynecol Reprod Biol; 2015 Aug; 191():62-7. PubMed ID: 26093349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The possibility of using progesterone receptor modulators in the treatment of myomas].
    Šimetka O; Klát J; Bajsová S
    Ceska Gynekol; 2016; 81(6):452-457. PubMed ID: 27918164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Applicability of selective progesterone receptor modulators in the treatment of uterine leiomyomata and their future role in the field of gynecology].
    Brazert M; Korman MP; Pawelczyk LA
    Ginekol Pol; 2013 Sep; 84(9):794-800. PubMed ID: 24191519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ulipristal acetate in the management of symptomatic uterine fibroids: facts and pending issues.
    Pérez-López FR
    Climacteric; 2015 Apr; 18(2):177-81. PubMed ID: 25390187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ulipristal acetate for uterine fibroid-related symptoms.
    Puchar A; Luton D; Koskas M
    Drugs Today (Barc); 2015 Nov; 51(11):661-7. PubMed ID: 26744741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate.
    Donnez J; Donnez O; Dolmans MM
    Expert Opin Drug Saf; 2016 Dec; 15(12):1679-1686. PubMed ID: 27740868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. With the advent of selective progesterone receptor modulators, what is the place of myoma surgery in current practice?
    Donnez J; Donnez O; Dolmans MM
    Fertil Steril; 2014 Sep; 102(3):640-8. PubMed ID: 25106762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Ulipristal acetate (Esmya): a selective modulator of progesterone receptors, new treatment of uterine fibromatosis].
    Nisolle M; Closon F; Firquet A; Top M; Pintiaux A
    Rev Med Liege; 2014 Apr; 69(4):220-5. PubMed ID: 24923103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective Progesterone Receptor Modulators for the Medical Treatment of Uterine Fibroids with a Focus on Ulipristal Acetate.
    Rabe T; Saenger N; Ebert AD; Roemer T; Tinneberg HR; De Wilde RL; Wallwiener M
    Biomed Res Int; 2018; 2018():1374821. PubMed ID: 30539001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ulipristal acetate versus placebo for fibroid treatment before surgery.
    Donnez J; Tatarchuk TF; Bouchard P; Puscasiu L; Zakharenko NF; Ivanova T; Ugocsai G; Mara M; Jilla MP; Bestel E; Terrill P; Osterloh I; Loumaye E;
    N Engl J Med; 2012 Feb; 366(5):409-20. PubMed ID: 22296075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive Factors of Response to Selective Progesterone Receptor Modulator (Ulipristal Acetate) in the Pharmacological Treatment of Uterine Fibroids.
    Szydłowska I; Marciniak A; Nawrocka-Rutkowska J; Rył A; Starczewski A
    Int J Environ Res Public Health; 2020 Jan; 17(3):. PubMed ID: 32012826
    [No Abstract]   [Full Text] [Related]  

  • 15. Drug safety evaluation of ulipristal acetate in the treatment of uterine fibroids.
    Tafi E; Scala C; Leone Roberti Maggiore U; Bizzarri N; Candiani M; Venturini PL; Ferrero S
    Expert Opin Drug Saf; 2015 Jun; 14(6):965-77. PubMed ID: 25772793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of ulipristal acetate (UPA) for the treatment of expulsion uterine myomas: report of two cases.
    Palaia I; Del Negro V; Fracassi A; Schiavi M; Di Donato V; Fischetti M; Muzii L; Benedetti Panici P
    Gynecol Endocrinol; 2020 Jul; 36(7):660-661. PubMed ID: 31878806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endometrial Effects of Prolonged Therapy with the Selective Progesterone Receptor Modulator Ulipristal Acetate: A Case Report.
    Levy G; Elkas J; Armstrong AY; Nieman LK
    J Reprod Med; 2016; 61(3-4):159-62. PubMed ID: 27172639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ulipristal acetate for the management of large uterine fibroids associated with heavy bleeding: a review.
    Donnez J; Courtoy GE; Donnez O; Dolmans MM
    Reprod Biomed Online; 2018 Aug; 37(2):216-223. PubMed ID: 29706284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What does non-eligibility for myoma surgery mean in the context of sequential prescription of ulipristal acetate?
    Pourcelot AG; Capmas P; Laberge P; Fernandez H
    J Gynecol Obstet Hum Reprod; 2020 Apr; 49(4):101688. PubMed ID: 31972353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vilaprisan for treating uterine fibroids.
    Melis GB; Neri M; Piras B; Paoletti AM; Ajossa S; Pilloni M; Marotto MF; Corda V; Saba A; Giancane E; Mais V
    Expert Opin Investig Drugs; 2018 May; 27(5):497-505. PubMed ID: 29718788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.